LONGEVA.

Semaglutide dosing schedule

semaglutide dosage

> Updated:

Semaglutide (preset)

Calculate the Semaglutide dose

The calculator is already set up for Semaglutide — adjust the dose or diluent volume for your vial.

Open calculator

In short

Semaglutide is given subcutaneously once weekly. Titration in published protocols: 0.25 mg in weeks 1–4, 0.5 mg in weeks 5–8, 1.0–1.7 mg in weeks 9–16 and 2.4 mg from week 17. The slow increase is not a formality: a faster jump to high doses more often brings on nausea and other gastrointestinal reactions of the GLP-1 class. In the diabetes schedule (Ozempic) the maximum is usually 2 mg; in the weight-management schedule (Wegovy) it is 2.4 mg.

Dosage in humans

Semaglutide is administered subcutaneously once weekly. The following is a generalized reference drawn from published studies and clinical GLP-1 titration protocols.

This is a concise reference to regimens described for adults; it is not an individual prescription.

A semaglutide dosing schedule is usually what people are actually looking for: the week-by-week dose increase, not a single fixed number. The table below shows the approximate pace of that titration from published protocols.

Period / conditionDoseEscalation
Weeks 1–40.25 mg weeklyStarting dose
Weeks 5–80.5 mg weeklyIncrease if tolerated
Weeks 9–161.0–1.7 mg weeklyGradual increase
From week 172.4 mg weeklyMaximum in this schedule

Brand note: in the diabetes brand schedule (Ozempic) the maximum is usually 2 mg once weekly, while the weight-management protocol (Wegovy) continues titration to a maintenance 2.4 mg by about week 16–17.

Practical dosing and effect details

The slow dose increase for semaglutide, from 0.25 mg to 2.4 mg over 16 weeks, mirrors the design of a real clinical trial. In Wilding and colleagues' study (New England Journal of Medicine, 2021), 1,961 adults with obesity had their dose raised every 4 weeks along the same sequence. Over 68 weeks, participants lost an average of 14.9% of body weight versus 2.4% in the placebo group.

The gradual pace is not a cosmetic detail. A faster jump straight to high doses more often brings on nausea and other gastrointestinal reactions typical of GLP-1-class peptides, so the trial dose climbed step by step rather than in one jump.

The weekly, rather than daily, interval between doses connects to dosing too: semaglutide's elimination half-life in blood runs about a week, so one dose sustains the level until the next and extra frequency adds nothing.

This is a generalized reference from a published trial, not a medical recommendation and not instructions for self-administration.

Frequently asked questions

What is the starting dose of semaglutide? 0.25 mg subcutaneously once weekly for the first 4 weeks. The dose is then raised every 4 weeks: 0.5 mg (weeks 5–8), 1.0–1.7 mg (weeks 9–16) and 2.4 mg from week 17.

What is the maximum semaglutide dose? In the weight-management schedule (Wegovy) it is 2.4 mg once weekly; in the diabetes schedule (Ozempic) the maximum is usually 2 mg once weekly.

How many U-100 syringe units is a dose? It depends on the concentration of the reconstituted vial: units = dose (mg) divided by concentration (mg/mL) times 100. For example, with a 5 mg vial in 2 mL (2.5 mg/mL), the 0.25 mg starting dose is 0.1 mL, i.e. 10 units, and 1 mg is 40 units.

Does semaglutide come in tablets? Yes, oral semaglutide exists (Rybelsus tablets, taken daily), but it is a separate schedule: tablet milligrams do not correspond to injection doses. This page covers weekly injections only; tablets are covered in a separate article on Rybelsus.

How to reconstitute

An example reconstitution for convenient dosing. The exact ratios depend on your vial. For research reference only — not medical guidance.

  1. 1Add the diluentUse bacteriostatic water. Example: 2 ml into a 5 mg vial.Semaglutide5 mg+ 2 mlDiluent
  2. 2Get the concentrationExample: 5 mg in 2 ml =Semaglutide2.5 mg/ml(2,500 mcg/ml)
  3. 3Work out the volume per doseFor example, for a 0.25 mg dose:0.25 mg = 0.1 ml= 10 u. (U-100)

This is only an example calculation. You can use a different diluent volume — plug your own numbers into the calculator. Open calculator →

Notes and safety

  • • Semaglutide is a research peptide. Human safety and efficacy data are limited.
  • • The regimens shown are based on publications and research protocols, not clinical recommendations.
  • • Individual reactions may vary. Published protocols typically start dosing at the lower end of the reported range.
  • • Not recommended for use with chronic illness, pregnancy, or breastfeeding.
  • • This information is for educational purposes and is not medical advice.
This is not medical advice — research information only.This material is not intended for diagnosis, treatment or prevention of disease.